Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$24.42 +1.5%	$21.90	$17.24 ▼ $27.94	$15.44B	0.95	1.14 million shs	2.12 million shs
RYTM Rhythm Pharmaceuticals	$101.68 +3.0%	$81.14	$43.57 ▼ $101.74	$6.56B	2.38	552,947 shs	682,917 shs
SMMT Summit Therapeutics	$26.01 +0.5%	$24.89	$11.76 ▼ $36.91	$19.22B	-1.06	2.83 million shs	1.49 million shs
TEVA Teva Pharmaceutical Industries	$18.79 +6.7%	$16.72	$12.47 ▼ $22.80	$20.20B	0.62	12.67 million shs	20.15 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+1.01%	+6.13%	+10.93%	+14.41%	-11.51%
RYTM Rhythm Pharmaceuticals	+1.55%	+0.86%	+11.36%	+59.17%	+116.40%
SMMT Summit Therapeutics	+2.05%	-3.68%	-1.78%	+0.39%	+110.15%
TEVA Teva Pharmaceutical Industries	+0.23%	+2.24%	+7.98%	+3.87%	-3.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.8719 of 5 stars	3.3	4.0	0.0	3.4	0.0	3.1
RYTM Rhythm Pharmaceuticals	3.7283 of 5 stars	2.5	3.0	4.3	3.2	0.8	0.6
SMMT Summit Therapeutics	2.3827 of 5 stars	4.3	1.0	0.0	1.8	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.5662 of 5 stars	3.6	4.0	0.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.60	53.97% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$101.57	-0.11% Downside
SMMT Summit Therapeutics	2.63	Moderate Buy	$32.85	26.28% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	31.51% Upside

Current Analyst Ratings Breakdown

Latest RYTM, TEVA, SMMT, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$21.00
8/19/2025	GMAB Genmab A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
8/18/2025	SMMT Summit Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$21.00
8/15/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
8/15/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
8/14/2025	SMMT Summit Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $34.00
8/7/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $100.00
8/6/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$119.00 ➝ $120.00
8/6/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$130.00 ➝ $135.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	5.02	$1.55 per share	15.71	$8.26 per share	2.96
RYTM Rhythm Pharmaceuticals	$130.13M	51.90	N/A	N/A	($0.18) per share	-564.89
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.35 per share	N/A
TEVA Teva Pharmaceutical Industries	$16.54B	1.30	$3.60 per share	5.22	$5.96 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.99	12.27	13.72	6.91	37.53%	21.03%	16.98%	11/5/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$3.01	N/A	N/A	N/A	-117.13%	-1,831.43%	-48.33%	11/4/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$1.01	N/A	N/A	N/A	N/A	-208.64%	-181.28%	10/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.15	1.04	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest RYTM, TEVA, SMMT, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	-$0.76	-$0.66	-$0.76	N/A	N/A
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.66	-$0.75	-$0.09	-$0.75	$43.72 million	$48.50 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	6.22	6.20
RYTM Rhythm Pharmaceuticals	N/A	2.79	2.64
SMMT Summit Therapeutics	N/A	5.13	5.13
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
RYTM Rhythm Pharmaceuticals	N/A
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
RYTM Rhythm Pharmaceuticals	6.10%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
RYTM Rhythm Pharmaceuticals	140	66.42 million	62.37 million	Optionable
SMMT Summit Therapeutics	110	742.85 million	112.17 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

RYTM, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

Aberdeen Group plc Acquires 286,206 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 21 at 4:18 AM | marketbeat.com

State of New Jersey Common Pension Fund D Buys 41,300 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 20 at 6:04 AM | marketbeat.com

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

August 20 at 3:51 AM | fool.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $4.49 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 19 at 5:01 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by National Bank of Canada FI

August 19 at 4:15 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Lifted by Menora Mivtachim Holdings LTD.

August 18 at 7:14 AM | marketbeat.com

National Pension Service Has $25.44 Million Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 5:01 AM | marketbeat.com

Resona Asset Management Co. Ltd. Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 4:49 AM | marketbeat.com

Nuveen LLC Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 4:31 AM | marketbeat.com

Invesco Ltd. Sells 1,377,277 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 4:04 AM | marketbeat.com

Tejara Capital Ltd Makes New $2.78 Million Investment in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 17, 2025 | marketbeat.com

Lord Abbett & CO. LLC Boosts Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 17, 2025 | marketbeat.com

Critical Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Dr. Reddy's Laboratories (NYSE:RDY)

August 17, 2025 | americanbankingnews.com

Public Sector Pension Investment Board Has $9.03 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16, 2025 | marketbeat.com

Virtu Financial LLC Buys Shares of 24,154 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16, 2025 | marketbeat.com

Deutsche Bank AG Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 14, 2025 | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 53,443 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 13, 2025 | marketbeat.com

Senores Pharma to acquire two products of USFDA approved ANDAs from Teva Pharma USA

August 13, 2025 | medicaldialogues.inM

Teva Pharmaceutical continues gains for seven straight sessions

August 12, 2025 | msn.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Todd Asset Management LLC

August 12, 2025 | marketbeat.com

30,900 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Purchased by ASR Vermogensbeheer N.V.

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM, TEVA, SMMT, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$24.42 +0.36 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$24.42 +0.00 (+0.02%)

As of 06:06 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Rhythm Pharmaceuticals NASDAQ:RYTM

$101.68 +2.98 (+3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$99.21 -2.47 (-2.43%)

As of 07:43 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$26.01 +0.14 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$26.22 +0.22 (+0.83%)

As of 07:41 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$18.79 +1.18 (+6.71%)

Closing price 03:59 PM Eastern

Extended Trading

$18.77 -0.02 (-0.12%)

As of 07:59 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time